China's Zenitar Biomedical closed a RMB 400 million (USD 56 million) Series B+ round led by Qiming Venture Partners, with participation from Gaorong Capital, Jifeng Ventures and others. The proceeds will advance three late-stage candidates: HDAC inhibitor purinostat in Phase III for lymphoma, JAK2/FLT3/CDK6 inhibitor flonoltinib for myelofibrosis, and five Phase II assets. Zenitar's AI-driven platforms integrate structural biology, AI-driven drug design, and organoid-PDX validation to accelerate first-in-class drug discovery.

Purinostat demonstrated 69% objective response rate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) Phase II trials, outperforming ADC combos. Flonoltinib showed ≥80% spleen volume reduction in myelofibrosis with potential disease-modifying effects. The Chengdu-based company holds 34 patents (17 international) and 19 IND approvals from China and US authorities. Founder Chen Lijuan highlighted plans for global expansion, with two candidates entering multinational Phase III studies in 2025.

According to PharmCube's NextBiopharm® database, Zenitar's portfolio covers 10 different disease areas. Click here to request a free trial for NextBiopharm®.